Cahill Represents PharmaMar in Exclusive License Agreement with Jazz Pharmaceuticals for Small Cell Lung Cancer Drug in the U.S.
Date: 12/19/19
Cahill represented PharmaMar, a Spanish biopharmaceutical company focused on oncology, in its agreement to exclusively license lurbinectedin to Jazz Pharmaceuticals Ireland Limited in the United States. Lurbinectedin is a late stage asset in relapsed small cell lung cancer pending FDA approval, with the potential to launch in 2020. Under the terms of the agreement, PharmaMar will receive an upfront payment of $200 million and is eligible to receive up to $800 million in potential milestone payments, in addition to royalties.
The Cahill team advising PharmaMar included Michael Weiss, who led the negotiations with Jazz and advised on intellectual property issues.